Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

Exelixis may have a steady source of revenue after cabozantinib – approved as Cabometyx and Cometriq – loses market exclusivity, after zanzalintinib delivered positive pivotal Phase III results in colorectal cancer.

Key Takeaways

Exelixis’s zanzalintinib got over the first hurdle on its way to the market, with positive topline results from the Phase III STELLAR-303 trial in previously treated non-MSI-high metastatic colorectal cancer.

The company announced June 22 topline results from the Phase III STELLAR-303 clinical trial combining zanzalintinib with Roche’s PD-L1 inhibitor...